Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Rang în acțiuni #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Preț acțiune
$0.0001
Ultima sincronizare: 2026-08-11
Capitalizare de piață
$36.84K
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-66.67%
Țară
US
Tranzacționează Amarantus BioScience Holdings, Inc. (AMBS)

Categorie

Câștiguri pentru Amarantus BioScience Holdings, Inc. (AMBS)
Câștiguri în 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Amarantus BioScience Holdings, Inc., câștigurile actuale ale companiei sunt 0. În anul 2026, compania a înregistrat un câștig de 0, egal cu câștigului din 2026, care a fost de 0. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Amarantus BioScience Holdings, Inc. din 2026 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE